RxDoctor Payments Data

Syed Hussain, MD

Neurology · Bedford, TXNPI 1346404803

Payments from drug & device makers

$16,218in general payments, 2019–2025

Across 691 payments — averaging $23.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Livanova USA, Inc.$2K
  • Medtronic$1K
  • Biogen$962
  • Amneal Pharmaceuticals LLC$935
  • EMD Serono, Inc.$733
  • plus $8K from 54 others

What the payments were for

  • Speaking & faculty fees$1191%
  • Travel & lodging$2,45315%
  • Food & beverage$13,51383%
  • Education$1321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)126$2,441
Livanova USA, Inc.8$2,163
Medtronic11$1,001
Biogen50$962
Amneal Pharmaceuticals LLC40$935
EMD Serono, Inc.65$733
Acadia Pharmaceuticals Inc36$671
Neurocrine Biosciences, Inc.27$645
Teva Pharmaceuticals USA, Inc.19$414
Grifols USA, LLC17$406
Eisai Inc.14$389
Novartis21$317
Pfizer17$305
Alnylam Pharmaceuticals Inc.14$302
Genentech USA, Inc.14$291
AstraZeneca(2 entities)16$278
UCB, Inc.13$238
Lilly USA, LLC13$211
GE HealthCare9$199
CSL Behring9$195
Merz Pharmaceuticals, LLC7$191
Ipsen Biopharmaceuticals, Inc8$189
Sanofi7$182
TG Therapeutics, Inc.8$172
Impel Pharmaceuticals Inc.11$164
Amgen(2 entities)9$156
Argenx US, Inc.7$140
Biohaven Pharmaceutical Holding Company Ltd.7$130
Abbott3$127
Bristol Myers Squibb7$119
SK Life Science, Inc.6$112
Vanda Pharmaceuticals Inc.4$107
Actelion Pharmaceuticals US, Inc.1$97
Boston Scientific4$95
Octapharma USA, Inc.4$94
Axsome Therapeutics, Inc.4$86
Supernus Pharmaceuticals, Inc.5$74
Amylyx Pharmaceuticals, Inc.3$66
Sunovion Pharmaceuticals Inc.4$65
Acorda Therapeutics, Inc3$54
Takeda Pharmaceuticals U.S.A., Inc.3$49
MDD US Operations, LLC3$45
Azurity Pharmaceuticals, Inc.3$44
Banner Life Sciences, LLC2$43
ANI Pharmaceuticals, Inc.2$39
Sumitomo Pharma America, Inc.2$38
Catalyst Pharmaceuticals, Inc.2$35
Johnson & Johnson(2 entities)2$35
Corium, LLC2$35
Avanir Pharmaceuticals, Inc.2$33
Sandoz1$27
Kyowa Kirin, Inc.1$26
Arbor Pharmaceuticals, Inc.2$24
Jazz Pharmaceuticals Inc.1$23
Invivyd Inc1$21
Tanabe Pharma America, Inc.1$21
Tersera Therapeutics LLC1$20
Otsuka America Pharmaceutical, Inc.1$19
Aprecia Pharmaceuticals, LLC1$19
NS Pharma, Inc.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,218 in reported general payments places this provider in the 70th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$262,853
Medicare patients
507
Services billed
17,073

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate44$300,098
AustedoDeutetrabenazine13$220,278
Austedo XrDeutetrabenazine25$195,552
RytaryCarbidopa/Levodopa99$143,513
IngrezzaValbenazine Tosylate15$124,996
Carbidopa-LevodopaCarbidopa/Levodopa869$25,624
Primidone496$19,980
Carbidopa-Levodopa ErCarbidopa/Levodopa400$10,442
Propranolol Hcl255$5,672
Memantine Hcl124$4,102
Gabapentin230$3,537
Donepezil Hcl233$2,792
Pregabalin37$2,582
RivastigmineRivastigmine Tartrate26$2,364
Ropinirole ErRopinirole Hcl19$1,613

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$414$415,83038 claims
Acadia Pharmaceuticals IncNuplazid$671$300,09844 claims
Amneal Pharmaceuticals LLCRytary$935$143,51399 claims
Neurocrine Biosciences, Inc.Ingrezza$645$124,99615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,246 neurology providers in Texas.

Other neurology in Bedford

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →